Since NQO1 protein levels are often increased in tumors as compared to healthy tissues [4,5,6], this enzyme emerges as an attractive target for cancer therapy, because NQO1 bioactivates compounds like β-lapachone leading to a selective cancer cells toxicity [8,23,24,25]. The gene discussed is NQO1; the disease is cancer.